Helicobacter pylori
Authors:
- Peter MalfertheinerPMPeter Malfertheiner
- Michael SelgradMSMichael Selgrad
- Jan BornscheinJBJan Bornschein
- 1 November 2012
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Gastroenterology
- Vol. 28 (6) , 608-614
Abstract
Progress continues in our understanding of the role of Helicobacter pylori infection in gastroduodenal as well as extragastric disorders. This review gives an overview on selected areas of the H. pylori infection and their clinical implications. Indications for therapy have been extended and now include idiopathic thrombocytopenic purpura, iron deficiency anemia, and vitamin B12 deficiency. New data are presented on the role of H. pylori in neurodegenerative disorders and in the metabolic syndrome. H. pylori is associated with a (small) increase in the risk for colorectal adenoma and colon cancer. The biggest challenge is the selection of new therapies and treatment strategies because of the increasing failure of standard triple therapies. The best option in high clarithromycin resistance areas is bismuth-based quadruple therapy. Probiotic bacteria and yeasts reduce adverse effects of standard H. pylori eradication regimens. In gastric cancer prevention, screening programs based on the serological detection of preneoplastic conditions may prove useful. New algorithms for preventing H. pylori-induced disease and eradicating the organism should be individualized.Keywords
This publication has 75 references indexed in Scilit:
- Molecular epidemiology, population genetics, and pathogenic role of Helicobacter pyloriInfection, Genetics and Evolution, 2012
- Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)Endoscopy, 2011
- Serological Prevalence of Helicobacter pylori Infection in Saxony-Anhalt, Germany, in 2010Clinical and Vaccine Immunology, 2011
- Bacterial chemotaxis modulates host cell apoptosis to establish a T-helper cell, type 17 (Th17)-dominant immune response in Helicobacter pylori infectionProceedings of the National Academy of Sciences, 2011
- Secular Trends in Helicobacter pylori Seroprevalence in Adults in the United States: Evidence for Sustained Race/Ethnic DisparitiesAmerican Journal of Epidemiology, 2011
- 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trialThe Lancet, 2011
- Plasma pepsinogens, antibodies against Helicobacter pylori, and risk of gastric cancer in the Shanghai Women's Health Study CohortBritish Journal of Cancer, 2011
- Epidemiology of Helicobacter pylori infection and Public Health ImplicationsHelicobacter, 2010
- The Role of Serum Pepsinogen and Gastrin Test for the Detection of Gastric Cancer in KoreaHelicobacter, 2008
- Gastric cancer screening using the serum pepsinogen test methodGastric Cancer, 2006